Because the CD2/CD58 interaction stabilizes the HRS/T synapses [75], monoclonal anti-CD2 antibodies, already in clinical trials for T-cell lymphomas and autoimmune conditions [102], may counter rosette formation and prove of some benefit in cHL. This evidence concerns the gene CD2 and classic Hodgkin lymphoma.